- Home
- ETON vs FULC Comparison
ETON vs FULC Comparison
Compare ETON & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- FULC
- Stock Information
- Founded
- ETON 2017
- FULC 2015
- Country
- ETON United States
- FULC United States
- Employees
- ETON 31
- FULC N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- FULC Health Care
- Exchange
- ETON Nasdaq
- FULC Nasdaq
- Market Cap
- ETON 498.8M
- FULC 469.0M
- IPO Year
- ETON 2018
- FULC 2019
- Fundamental
- Price
- ETON $18.25
- FULC $8.60
- Analyst Decision
- ETON Strong Buy
- FULC Buy
- Analyst Count
- ETON 3
- FULC 7
- Target Price
- ETON $29.67
- FULC $9.14
- AVG Volume (30 Days)
- ETON 261.2K
- FULC 536.5K
- Earning Date
- ETON 11-06-2025
- FULC 10-29-2025
- Dividend Yield
- ETON N/A
- FULC N/A
- EPS Growth
- ETON N/A
- FULC N/A
- EPS
- ETON N/A
- FULC N/A
- Revenue
- ETON $58,181,000.00
- FULC N/A
- Revenue This Year
- ETON $105.25
- FULC N/A
- Revenue Next Year
- ETON $40.84
- FULC N/A
- P/E Ratio
- ETON N/A
- FULC N/A
- Revenue Growth
- ETON 85.40
- FULC 2752.05
- 52 Week Low
- ETON $8.24
- FULC $2.32
- 52 Week High
- ETON $23.00
- FULC $10.11
- Technical
- Relative Strength Index (RSI)
- ETON 46.28
- FULC 57.67
- Support Level
- ETON $18.00
- FULC $8.29
- Resistance Level
- ETON $18.92
- FULC $10.09
- Average True Range (ATR)
- ETON 0.87
- FULC 0.69
- MACD
- ETON -0.12
- FULC -0.03
- Stochastic Oscillator
- ETON 40.66
- FULC 78.89
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.